Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer - No Study Results Posted - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer

This study has been completed.

Study NCT00053365 Information provided by National Cancer Institute (NCI)

First Received: January 27, 2003 Last Updated: April 26, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Publications:

Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. Int J Gynecol Cancer. 2010 Oct;20(7):1137-41.

Back to top of Main Content